Arca
Skip to content
Tools
Tools

Alopecia

Drug research and approvals for alopecia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 91 studies of alopecia are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 91
  • Trials authorized in Canada: 26
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 91 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

Phase 3 2

Phase 2 12 of 16

Phase 1 or earlier 4

How its trials ended

533 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 98 whose ending is known, 43% met their primary endpoint, 4% missed it and 53% stopped early.

  • Completed, result not reported21941%
  • Ongoing13425%
  • Status unknown8215%
  • Met its primary endpoint428%
  • Stopped: other or unclear326%
  • Stopped: enrollment or feasibility102%
  • Stopped: sponsor or business decision61%
  • Missed its primary endpoint41%
  • Stopped: lack of efficacy41%

Trials authorized in Canada

The 10 newest of 26; search them all in Canada trials
Sep 15, 2026A randomized, double-blind, single-center, vehicle-controlled, phase 1 study to assess safety and effects of PP405 on follicular unit activity in adult males…PP405Pelage PharmaceuticalsOngoing
Sep 15, 2026A randomized, multicenter, double-blind, vehicle-controlled, phase 2/3 study to assess efficacy and long-term safety of PP405 in adult males with androgenetic…PP405Pelage PharmaceuticalsPending
Apr 15, 2026A phase 2, randomized, multicenter, double-blind, placebo-controlled proof of concept study to investigate efficacy and safety of LY4005130 in adult…LY4005130Eli LillyOngoing
Dec 16, 2025A phase 1, open-label, maximal use trial to assess the pharmacokinetics, safety, and tolerability of PP405 topical gel 0.05% in adult participants with…PP405Pelage PharmaceuticalsClosed
Aug 15, 2025A double-blind, randomized, placebo-controlled multicenter study to evaluate the efficacy and safety of deuruxolitinib in adolescent patients with severe…Deuruxolitinib (CTP-543)Sun Pharmaceutical IndustriesOngoing
Jun 25, 2025A phase 3 randomized, double-blind, placebo-controlled study to investigatethe efficacy and safety of ritlecitinib in pediatric participants 6 to less than 12…Ritlecitinib (PF-06651600)PfizerClosed
Jun 13, 2025A phase 2a, randomized, double-blind, placebi-controlled, proof-of-concept trial with part b open-label extension of ADX-914 for the treatment of severe…ADX-914Q32 Bio IncOngoing
Jan 10, 2025A phase 1b/2a, intraindividual study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ALD-102 solution for intradermal…ALD-102Aldena Therapeutics (Uk), Ltd.Ongoing
May 8, 2024A phase 2, randomized, double-blind, placebo-controlled, parallel group, 3- arm, multinational, multicenter, proof-of-concept study to evaluate the efficacy…Amlitelimab (SAR445229)Sanofi-Aventis Canada IncClosed
Jan 30, 2024A phase 2b, randomized, double-blind, parallel group, placebo-controlled 60- week study to evaluate the efficacy and safety of rezpegaldesleukin in treatment…Rezpegaldesleukin (NKTR-358)Nektar TherapeuticsOngoing

FDA orphan designations

Approved first, then open designations, newest first
Dec 21, 2017Trafermin in combination with plasma and platelet rich…Treatment of alopecia areata in pediatric patientsHCell, Inc.Designated
Jun 13, 2003DiphenylcyclopenoneTreatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])Lloyd E. King, Jr.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Sep 15, 2023LitfuloRitlecitinibPfizer Europe MA EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.